“Bimekizumab Efficacy by Prior Biologic Treatment in Patients with Moderate to Severe Hidradenitis Suppurativa: 48-Week Pooled Data from the Randomized, Double-Blind, Placebo-Controlled, Multicenter BE HEARD I and II Phase 3 Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s349. doi:10.25251/skin.8.supp.349.